SCHEMBL1983570

SCHEMBL1983570

CCc1c(C(=O)O)nn(-c2ccc(OC)cc2)c1-c1ccc(Br)o1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.46
CCNA2 P20248 2/20 0.43
CDK2 P24941 2/20 0.43
CCNA1 P78396 2/20 0.43
MAPT P10636 3/20 0.40
ALDH1A1 P00352 2/20 0.40
PDE4D Q08499 1/20 0.40
ADORA1 P30542 1/20 0.40
PTGS2 P35354 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
NPBWR1 P48145 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
GAA P10253 1/20 0.38
THRB P10828 1/20 0.38
RECQL P46063 1/20 0.38
LMNA P02545 1/20 0.38
HPGD P15428 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1984520 0.88 TP53 (0.46) TP53CCNA2CDK2CCNA1MAPT
SCHEMBL1987194 0.87 TP53 (0.46) TP53CCNA2CDK2CCNA1MAPT
SCHEMBL1987766 0.87 CYP1A2 (0.43) MAPTPTGS2SMN1; SMN2MEN1KMT2A
SCHEMBL1984692 0.86 TP53 (0.48) TP53CCNA2CDK2CCNA1MAPT
SCHEMBL1989096 0.83 TP53 (0.44) TP53CCNA2CDK2CCNA1MAPT
SCHEMBL1987723 0.80 TP53 (0.45) TP53CCNA2CDK2CCNA1MAPT
SCHEMBL1988653 0.79 TP53 (0.44) TP53CCNA2CDK2CCNA1MAPT
SCHEMBL1987136 0.79 TP53 (0.46) TP53CCNA2CDK2CCNA1MAPT
SCHEMBL1983923 0.78 MAPT (0.46) TP53CCNA2CDK2CCNA1MAPT
SCHEMBL1984488 0.77 TP53 (0.48) TP53CCNA2CDK2CCNA1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1602656-A1 PYRAZOLE DERIVATIVES HAVING AFFINITY FOR CB1 AND/OR CB2 RECEPTORS NEUROSCIENZE PHARMANESS S.C. a R.L. (IT) 2005-12-07 EP claimed
US-20050261281-A1 Pharmaceutical compounds MIDCAP FUNDING III, LLC 2005-11-24 US claimed
US-8227620-B2 Pharmaceutical compounds NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) 2012-07-24 US disclosed
EP-1602656-B1 PYRAZOLE DERIVATIVES HAVING AFFINITY FOR CB1 AND/OR CB2 RECEPTORS NEUROSCIENZE PHARMANESS S C A R L (IT) 2011-06-29 EP disclosed
US-20100105896-A1 PHARMACEUTICAL COMPOUNDS Neuroscienze Pharmaness S.C.a.R.I. (IT) 2010-04-29 US disclosed
US-7659407-B2 pyrazole derivatives having affinity for cannabinoidergic CB1 and/or CB2 receptors; immune disorders, osteoporosis, renal ischemia, inflammation,transplant rejection; 5-(5-Chloro-thiofen-2-yl)-1-(4-methoxy-phenyl)-4-methyl-1H-pyrazol-3-carboxylic acid Neuroscienze Pharmaness S.C.a.R.I. (IT) 2010-02-09 US disclosed
EP-1602656-A1 PYRAZOLE DERIVATIVES HAVING AFFINITY FOR CB1 AND/OR CB2 RECEPTORS NEUROSCIENZE PHARMANESS S.C. a R.L. (IT) 2005-12-07 EP disclosed
US-20050261281-A1 Pharmaceutical compounds MIDCAP FUNDING III, LLC 2005-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105896-A1 PHARMACEUTICAL COMPOUNDS CNR1, CNR2, OPRD1 TP53 4663/4885CCNA2 1817/4885CDK2 1140/4885
US-20050261281-A1 Pharmaceutical compounds CNR1, CNR2, OPRD1 TP53 4717/4885CCNA2 1347/4885CDK2 1185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.